A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary CholangitisFrederik Nevens, Д. А. Шапиро, Velimir A. Luketic et al.|New England Journal of Medicine|2016Cited by 1.1k
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and ObesityXiaoxin X. Wang, Moshe Levi, Dong Wang et al.|Journal of the American Society of Nephrology|2017Cited by 222
Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver DiseaseRachel H. McMahan, Hugo R. Rosen, Xiaoxin X. Wang et al.|Journal of Biological Chemistry|2013Cited by 218
Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes ModelXiaoxin X. Wang, Moshe Levi, Tao Jiang et al.|Diabetes|2010Cited by 187
Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 AgonistGiovanni Rizzo, Luciano Adorini, Daniela Passeri et al.|Molecular Pharmacology|2010Cited by 185